Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study

Ying Li1,2 &ast;, Jia-Jing Lu1,2 &ast;, Xiao-Yuan Zhong1,2 &ast;, Ying-Yuan Yu1,2 &ast;, Ning Yu,1,2 Yu Wang,1,2 Xue-Mei Yi,1,2 Yang-Feng Ding,1,2 Yu-Ling Shi1,2 1Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China; 2I...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Li Y, Lu JJ, Zhong XY, Yu YY, Yu N, Wang Y, Yi XM, Ding YF, Shi YL
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Dove Medical Press 2022-10-01
Rangatū:	Clinical, Cosmetic and Investigational Dermatology
Ngā marau:	biologics drug survival real-world psoriasis ixekizumab secukinumab guselkumab adalimumab.
Urunga tuihono:	https://www.dovepress.com/drug-survival-outcomes-associated-with-the-real-world-use-of-ixekizuma-peer-reviewed-fulltext-article-CCID
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study

Ngā tūemi rite